Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Oveporexton is a testament to Takeda's strength in discovering and developing a potential new class of medicines for difficult to treat diseases such as narcolepsy type 1.
Share
'We are thrilled to reach this pivotal milestone for the oveporexton program. Oveporexton is a testament to Takeda's strength in discovering and developing a potential new class of medicines for difficult to treat diseases such as narcolepsy type 1,' said Christophe Weber, president and chief executive officer at Takeda. "Our leadership in orexin biology and building a multi-asset orexin franchise with transformative potential will position Takeda for long-term future growth.'
The FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies were two large, global Phase 3 studies conducted in 19 countries. Both studies achieved statistically significant improvement compared to placebo with p-values of <0.001 for all primary and secondary endpoints across all doses at week 12. The primary and secondary endpoints measuring objective and patient reported improvements in wakefulness, excessive daytime sleepiness, cataplexy, ability to maintain attention, overall quality of life and daily life functions demonstrate statistically significant and clinically meaningful improvements achieving near normal ranges across the broad range of symptoms investigated.
Oveporexton was generally well-tolerated with a safety profile from the Phase 3 studies overall consistent with oveporexton studies to date including the Phase 2b study. No serious treatment-related adverse events were reported. The most common adverse events were insomnia, urinary urgency and frequency. More than 95 percent of the participants who completed the studies enrolled in the ongoing long-term extension (LTE) study.
'We are grateful to the patients who took part in these clinical studies and to their families, the investigators and clinical staff. The studies were accelerated at an unprecedented pace with the aim to bring this potential treatment to people living with narcolepsy type 1 as quickly as possible,' said Andy Plump, M.D., Ph.D., president of R&D at Takeda. 'The comprehensive assessments from our Phase 3 studies build on the transformative results we saw with our Phase 2b study with most participants reaching normative ranges and reporting clinically meaningful improvement across a broad range of symptoms at the end of the 12-week treatment period. The positive results also reinforce the continued momentum for our late-stage pipeline, which we believe will deliver value to the patients we serve around the world.'
Takeda intends to present the results at upcoming medical congresses and plans to submit a New Drug Application with the United States Food and Drug Administration and additional global regulatory authorities in fiscal year 2025.
Results from the Phase 3 studies have no significant impact on the full year consolidated forecast for the fiscal year ending March 31, 2026.
About Narcolepsy Type 1 (NT1) and Orexin Science
NT1 is a chronic, rare neurological disease that results in a range of debilitating symptoms including excessive daytime sleepiness (EDS), cataplexy, disrupted nighttime sleep, sleep paralysis and hallucinations upon falling asleep or waking. Additionally, individuals living with NT1 often report cognitive symptoms, including difficulty thinking clearly, remembering, concentrating and paying attention. NT1 is caused by loss of the orexin-producing neurons in the brain, which regulate wakefulness and sleep, and is also believed to be essential to other functions such as attention through activation of orexin receptors. Currently, the standard of care is limited to symptomatic therapies that may only partially address some of the symptoms people face.
About Oveporexton (TAK-861)
Oveporexton (TAK-861) is an investigational orexin receptor 2 (OX2R)-selective agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency that causes narcolepsy type 1 (NT1). By activating OX2Rs, oveporexton is designed to promote wakefulness and reduce abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy, to address the broad spectrum of daytime and nighttime symptoms.
About the FirstLight and RadiantLight Phase 3 Studies
FirstLight (TAK-861-3001; NCT06470828) and RadiantLight (TAK-861-3002; NCT06505031) are global, multicenter, placebo-controlled studies to evaluate the efficacy, safety and tolerability of oveporexton compared to placebo in patients with narcolepsy type 1 (NT1) over 12 weeks. The studies were conducted in 19 countries with enrollment completed within six months. The FirstLight study enrolled 168 participants randomized to one of three dosing arms (high dose, low dose and placebo). The RadiantLight study enrolled 105 participants randomized to two dosing arms (high dose and placebo). The primary endpoint in both studies was improvement in excessive daytime sleepiness (EDS) as measured by the Maintenance of Wakefulness Test (MWT), a standard measure of wakefulness. Key secondary endpoints included improvement in EDS as measured by the Epworth Sleepiness Scale (ESS) and in the Weekly Cataplexy Rate (WCR), a measure evaluating cataplexy. The studies also evaluated the effect of oveporexton on participants' ability to maintain attention, participants' overall quality of life, the spectrum of narcolepsy symptoms and daily life functions, as well as the safety and tolerability of oveporexton.
About Takeda's Orexin Agonists for Sleep-Wake Disorders
Takeda is leading the field of orexin science with a multi-asset franchise. Orexin is a key regulator of sleep and wake patterns and contributes to other essential functions including attention, mood, metabolism and respiration. Oveporexton (TAK-861) is the lead investigational orexin receptor 2 (OX2R) agonist asset in Takeda's orexin franchise and received Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in narcolepsy type 1 (NT1) from the U.S. Food and Drug Administration and the Center for Drug Evaluation of China's National Medical Products Administration. The company is also investigating other orexin agonists in populations with orexin levels in the normal range, including TAK-360, an oral OX2R agonist initially being investigated for the treatment of narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other potential indications where orexin signaling is implicated.
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Important Notice
For the purposes of this notice, 'press release' means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Is Entergy Corporation's (NYSE:ETR) 8.7% ROE Better Than Average?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). To keep the lesson grounded in practicality, we'll use ROE to better understand Entergy Corporation (NYSE:ETR). Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. How Do You Calculate Return On Equity? The formula for return on equity is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Entergy is: 8.7% = US$1.3b ÷ US$16b (Based on the trailing twelve months to March 2025). The 'return' is the yearly profit. That means that for every $1 worth of shareholders' equity, the company generated $0.09 in profit. See our latest analysis for Entergy Does Entergy Have A Good ROE? By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. The image below shows that Entergy has an ROE that is roughly in line with the Electric Utilities industry average (9.2%). That isn't amazing, but it is respectable. Although the ROE is similar to the industry, we should still perform further checks to see if the company's ROE is being boosted by high debt levels. If a company takes on too much debt, it is at higher risk of defaulting on interest payments. You can see the 3 risks we have identified for Entergy by visiting our risks dashboard for free on our platform here. How Does Debt Impact Return On Equity? Most companies need money -- from somewhere -- to grow their profits. The cash for investment can come from prior year profits (retained earnings), issuing new shares, or borrowing. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders' equity. That will make the ROE look better than if no debt was used. Entergy's Debt And Its 8.7% ROE Entergy clearly uses a high amount of debt to boost returns, as it has a debt to equity ratio of 1.99. Its ROE is quite low, even with the use of significant debt; that's not a good result, in our opinion. Debt increases risk and reduces options for the company in the future, so you generally want to see some good returns from using it. Conclusion Return on equity is one way we can compare its business quality of different companies. A company that can achieve a high return on equity without debt could be considered a high quality business. All else being equal, a higher ROE is better. But when a business is high quality, the market often bids it up to a price that reflects this. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So you might want to check this FREE visualization of analyst forecasts for the company. Of course Entergy may not be the best stock to buy. So you may wish to see this free collection of other companies that have high ROE and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
The Smartest Dividend Stock to Buy With $1,000 Right Now
Key Points Dividend stocks that reliably increase their dividends are the perfect pick for income investors. Buying reliable dividend stocks when they have historically high yields is ideal. Universal Health Realty Income Trust's 7.4% dividend yield is near the highest levels of the past decade. 10 stocks we like better than Johnson & Johnson › If you are a dividend investor looking to maximize the income your portfolio generates, you will want to do a deep dive on Universal Health Realty Income Trust (NYSE: UHT). It has a historically high 7.4% dividend yield and a great track record of dividend growth to back it up. The dividend stock won't be right for every income investor, but for a select few it could be the smartest dividend stock to buy right now. What makes a dividend stock attractive? One of the first things that income investors look for is dividend yield. Universal Health Realty Income Trust has that factor pegged, with a huge 7.4% dividend yield. But some reference points will help. The S&P 500 (SNPINDEX: ^GSPC) has an itty bitty yield of 1.3%. The average healthcare stock has a yield of 1.8%. And the average real estate investment trust (REIT) has a yield of roughly 4.1%. Very clearly, Universal Health Realty is more attractive on the yield front. But yield has to be considered along with reliability. For example, one of the most reliable dividend-paying healthcare stocks is Johnson & Johnson (NYSE: JNJ), with 63 years of annual dividend hikes behind it. Next up is Becton, Dickinson (NYSE: BDX), with 53 years of hikes. Those two companies are Dividend Kings, an elite status that Universal Health Realty simply can't claim. That said, Johnson & Johnson's yield is 3.4% and Becton, Dickinson's yield is an even smaller 2.4%. Universal Health Realty's dividend has been hiked annually for four decades. That's a pretty good streak, even though it isn't yet a Dividend King, when you add in the real estate investment trust's huge yield. A $1,000 investment will get you around 24 shares of the healthcare-focused REIT. Universal Health Realty Trust is for income right now So a lofty yield and a strong dividend history make Universal Health Realty Trust attractive. It is extra attractive right now because the yield is near the highest levels of the past decade, suggesting the stock is on the sale rack. But there's just one small problem: Dividend growth has never been a big selling point here. As the chart above highlights, both JNJ's and Becton, Dickinson's dividend growth has been far superior to that of Universal Health Realty Trust. The goal for Universal Health Realty Trust isn't rapid dividend growth, it is reliable growth. It is a slow and steady tortoise, and that is likely all it will ever be. And that brings up the second big issue that investors need to know about. Universal Health Realty Trust is externally managed by Universal Health Services (NYSE: UHS), the REIT's largest tenant. There are very clear issues with conflicts of interest that have to be considered. However, the 40-year track record of slow and steady dividend growth is an indication of what Universal Health Services is doing here. More attractive than it was, not for all, but smart for some The interesting thing here is that prior to the coronavirus pandemic, Universal Health Realty's dividend yield was a tiny 2.1% or so. At that point, investors were way too optimistic about the REIT given the tortoise-like nature of the dividend. But, today, with the yield at 7.4%, this healthcare stock is a lot more attractive. It won't be right for every dividend investor, given the management structure and that tortoise-like dividend growth. For dividend growth investors, JNJ or Becton, Dickinson will be more appropriate. However, if you are trying to maximize the income you generate from your portfolio today and you are looking for a healthcare investment, Universal Health Realty Trust could be perfect for your portfolio if you have $1,000 or $10,000 to invest. Should you invest $1,000 in Johnson & Johnson right now? Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy. The Smartest Dividend Stock to Buy With $1,000 Right Now was originally published by The Motley Fool Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
3 hours ago
- Yahoo
3 Dividend Stocks to Hold for the Next 10 Years
Key Points American Express gets money from its card and also by providing loans. Coca-Cola's global footprint is a strength. McDonald's is the world's top fast-food franchise and plans to open 2,200 new locations this year. 10 stocks we like better than Coca-Cola › I've always appreciated dividend stocks as a solid strategy for any investment portfolio. While I recognize the importance of growth stocks (and hold several of them), stocks that represent companies that pay a solid, consistent dividend also are an important tool for growing wealth. The best thing about dividend stocks is that they're ideal for all types of investors. If you're just starting out or a few years into building your portfolio, dividends are a great way to turbocharge your savings. In addition to the gains you get when the stock price rises, you can take the quarterly dividend payout and reinvest it, adding to your positions and growing wealth more quickly. If you're in retirement and starting to draw down your investments, dividend stocks are an ideal way to keep the income flowing. Many investors in retirement use dividend payouts to pay for living expenses, which keeps them from drawing down their retirement funds too quickly. There are hundreds of dividend stocks from which to choose, but I prefer ones from established companies that provide consistent payouts. Here are three that are worth considering today. 1. Coca-Cola I like Coca-Cola (NYSE: KO) because it has a dominant position in the beverage industry, holding the No. 1 position in 2024 with a 48% market share, according to Statista. And there's plenty to drink aside from the famous Cola-Cola carbonated beverage. The company also sells bottled water, sports drinks, tea, juices and a line of alcoholic beverages. In all, the company has 30 brands that are each valued at a minimum of $1 billion. Revenue in the first quarter declined 2% to $11.1 billion because of slumping sales in North America. But Coca-Cola was able to mitigate losses by increasing sales in China, India, and Brazil -- and the company's global footprint will continue to be a hedge against weakness in any one geographic area. Net income attributable to shareholders as $3.33 billion and $0.77 per share, up from $3.18 and $0.74 per share in the first quarter of 2024. Coca-Cola also offers a strong dividend yield of 2.9%. 2. American Express Like Coca-Cola, American Express (NYSE: AXP) is a favored dividend stock held by Warren Buffett in Berkshire Hathaway's portfolio. Berkshire currently has a dominant 21.6% stake in American Express, holding 151.6 million shares. American Express stands out from other credit card companies because it caters to a more affluent base, with a stronger emphasis on its gold and platinum cards, as well as corporate accounts. As an American Express customer, I can attest that the travel perks are extremely generous. But American Express also is different in how it makes money. Not only does it issue cards like Visa and Mastercard, but it operates its own payment network that allows it to extend credit and earn income from the interest it charges on loans. Revenue in the first quarter was $2.6 billion and $3.64 per share, up from $2.4 billion and $3.33 billion in the same quarter of 2024. American Express also has a dividend yield of 1%. 3. McDonald's McDonald's (NYSE: MCD) is the dominant fast-food chain in the world, boasting more than 43,000 locations in over 100 countries. From its start as a single restaurant in California, McDonald's revolutionized the industry with its consistent standards and franchise model. After a customer backlash last year over higher prices and inflation, McDonald's has been aggressive in pushing value menus and deals, including the return of its chicken snack wraps this spring. It's also driving traffic through its loyalty program, which includes 175 million customers who are active at least every 90 days within 60 global markets. McDonald's attributes $30 billion in overall sales to its loyalty membership program. Global sales were down 0.1% in 2024, and that trend continued in the first quarter of 2025, as global sales dropped 0.1% from a year ago. In the U.S., sales were down 3.6% from a year ago, and earnings per share of $2.60 was down 2% from a year ago. However, McDonald's still plans to open 2,200 new locations in 2025, which it says will boost its global sales growth by more than 2% this year. With its 2.4% dividend yield, McDonald's is a quality dividend stock for a long-term investor. Should you buy stock in Coca-Cola right now? Before you buy stock in Coca-Cola, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Coca-Cola wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 American Express is an advertising partner of Motley Fool Money. Patrick Sanders has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Mastercard, and Visa. The Motley Fool has a disclosure policy. 3 Dividend Stocks to Hold for the Next 10 Years was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
